Taysha Gene Therapies Share Holder Equity 2020-2024 | TSHA

Taysha Gene Therapies share holder equity from 2020 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
Taysha Gene Therapies Annual Share Holder Equity
(Millions of US $)
2023 $75
2022 $1
2021 $95
2020 $251
2019 $-0
Taysha Gene Therapies Quarterly Share Holder Equity
(Millions of US $)
2024-09-30 $89
2024-06-30 $109
2024-03-31 $54
2023-12-31 $75
2023-09-30 $-49
2023-06-30 $-37
2023-03-31 $-15
2022-12-31 $1
2022-09-30 $11
2022-06-30 $33
2022-03-31 $51
2021-12-31 $95
2021-09-30 $140
2021-06-30 $186
2021-03-31 $223
2020-12-31 $251
2020-09-30 $268
2020-06-30 $0
2020-03-31 $0
2019-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.506B $0.015B
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.395B 6.36
Dr Reddy's Laboratories (RDY) India $11.853B 22.68
BridgeBio Pharma (BBIO) United States $4.426B 0.00
Bausch Health Cos (BHC) Canada $2.931B 2.13
Amphastar Pharmaceuticals (AMPH) United States $2.186B 13.14
Supernus Pharmaceuticals (SUPN) United States $2.000B 27.23
Personalis (PSNL) United States $0.245B 0.00
Assembly Biosciences (ASMB) United States $0.096B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.006B 0.00
Teligent (TLGT) United States $0.000B 0.00